Alpelisib (BYL719)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • VIJOICE: adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy (accelerated approval)
Product first approved 2019Outside this platform's coveragenovartis.com
EU
  • Piqray with fulvestrant for HR-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer after progression on endocrine therapy
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Breast Cancer
NCT05063786 · Spanish Breast Cancer Research Group
2021-09-14 – 2025-12-23 · Advanced Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
Other / comorbidity
NCT04251533 · Novartis Pharmaceuticals
2020-06-08 – 2026-02-05 · Triple Negative Breast Neoplasms
What this study did
NCT04729387 · Novartis Pharmaceuticals
2021-07-22 – 2026-01-19 · Ovarian Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05948943 · Novartis Pharmaceuticals
2023-11-24 – 2033-05-02 · Lymphatic Malformations
What this study did
Phase 2 (35)
Breast Cancer
NCT04216472 · M.D. Anderson Cancer Center
2020-07-10 – 2025-09-22 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma
What this study did
NCT01923168 · Novartis Pharmaceuticals
2014-03-11 – 2017-07-08 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07679269 · Novartis Pharmaceuticals
2026-12-15 – 2032-04-20 · PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
What this study did
NCT05933395 · Dartmouth-Hitchcock Medical Center
2024-09-23 – 2031-10 · Advanced Breast Cancer
What this study did
NCT05564377 · National Cancer Institute (NCI)
2023-04-07 – 2030-07-01 · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT05392608 · Borstkanker Onderzoek Groep
2022-06-02 – 2028-03 · Neoplasm, Breast, Congenital, Familial and Genetic Disorders
What this study did
NCT05090358 · Memorial Sloan Kettering Cancer Center
2021-10-08 – 2027-10-08 · Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
What this study did
NCT04524000 · Novartis Pharmaceuticals
2021-01-08 – 2027-02-27 · Advanced Breast Cancer
What this study did
NCT04544189 · Novartis Pharmaceuticals
2021-01-20 – 2027-01-29 · Breast Neoplasms
What this study did
NCT04762979 · Marina N Sharifi
2021-02-12 – 2026-05 · Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT05967286 · National Cancer Institute (NCI)
2023-10-23 – 2025-04-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Unresectable HER2-Negative Breast Carcinoma
What this study did
NCT04300790 · MedSIR
2020-10-23 – 2025-03-16 · Breast Cancer
What this study did
NCT05966584 · Memorial Sloan Kettering Cancer Center
2023-07-06 – 2024-08-02 · Breast Cancer
What this study did
NCT05101564 · Jennifer Lee Caswell-Jin
2023-03-20 – 2024-06-03 · Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
What this study did
NCT02506556 · Peter MacCallum Cancer Centre, Australia
2015-09-07 – 2021-10-26 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT06997588 · Novartis Pharmaceuticals
2025-10-09 – 2031-06-18 · PIK3CA-related Overgrowth Spectrum (PROS)
What this study did
NCT04589650 · Novartis Pharmaceuticals
2021-04-19 – 2031-01-09 · PIK3CA-related Overgrowth Spectrum (PROS)
What this study did
NCT07543822 · Children's Hospital of Philadelphia
2025-08-27 – 2030-10-27 · Vascular Anomalies, Vascular Anomaly, TIE2/PIK3CA Pathway Driven Vascular Anomalies
What this study did
NCT05154487 · GOG Foundation
2024-09-11 – 2028-11-01 · Endometroid Endometrial Cancer
What this study did
NCT06145308 · Peking Union Medical College
2023-08-15 – 2028-07-10 · Salivary Gland Carcinoma, Precision Therapy
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT04980833 · Novartis Pharmaceuticals
2022-01-27 – 2027-06-22 · PIK3CA-related Overgrowth Spectrum (PROS)
What this study did
NCT06739395 · Tianjin Medical University Second Hospital
2024-11-01 – 2027-05-01 · Solid Tumor, Precision Medicine
What this study did
NCT05983159 · Murdoch Childrens Research Institute
2024-09-13 – 2027-05 · Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations, Venous Malformation, Lymphatic Malformation, Low Flow, Lymphatic Malformation, Lymphangioma, Arteriovenous Malformations, Venous Malformation, Low Flow, Cystic Hygroma, Vascular Anomaly, Vascular Anomalies, PI3K Gene Mutation, MAP2K1 Gene Mutation, PIK3CA-related Overgrowth Spectrum, Arteriovenous Malformation (AVM), KRAS G12C, KRAS G12D
What this study did
NCT05577754 · Centre Hospitalier Universitaire Dijon
2022-11-28 – 2027-03 · Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
What this study did
NCT03601507 · University of Arizona
2019-03-11 – 2022-05-24 · CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT03292250 · Seoul National University Hospital
2017-09-10 – 2022-03-10 · HNSCC, Head and Neck Neoplasms
What this study did
NCT02276027 · Novartis Pharmaceuticals
2015-01-20 – 2019-10-15 · Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
What this study did
NCT02145312 · Yonsei University
2016-10-01 – 2019-05 · Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
What this study did
NCT01719380 · Pfizer
2012-11-23 – 2019-02-12 · Colorectal Cancer
What this study did
Phase 1/2 (11)
Breast Cancer
NCT05230810 · Criterium, Inc.
2022-08-25 – 2026-06-30 · HER2-positive Metastatic Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05563220 · Stemline Therapeutics, Inc.
2023-01-24 – 2028-12-28 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01872260 · Novartis Pharmaceuticals
2013-10-22 – 2027-02-26 · Breast Cancer
What this study did
NCT02379247 · Priyanka Sharma
2015-02 – 2022-03 · Breast Cancer
What this study did
Other / comorbidity
NCT04997902 · Kura Oncology, Inc.
2021-12-07 – 2025-08-29 · HNSCC
What this study did
NCT04753203 · Korean Cancer Study Group
2021-02-28 – 2025-02-28 · Metastatic Colorectal Cancer, PIK3CA Gene Mutation
What this study did
NCT04526470 · Seoul National University Bundang Hospital
2020-09-01 – 2024-12 · Solid Tumor, Stomach Cancer
What this study did
NCT02298595 · Julie E. Bauman, MD, MPH
2016-08 – 2024-08 · Carcinoma, Squamous, Squamous Cell Carcinoma, Oropharyngeal Neoplasms, Oropharyngeal Cancer
What this study did
NCT01708161 · Novartis Pharmaceuticals
2012-11-27 – 2017-06-01 · PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
What this study did
NCT01602315 · Novartis Pharmaceuticals
2012-11-12 – 2016-09-16 · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
Phase 1 (38)
Breast Cancer
NCT02167854 · Memorial Sloan Kettering Cancer Center
2014-06-16 – 2021-07-07 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06545682 · M.D. Anderson Cancer Center
2024-10-15 – 2029-08-03 · Melanoma (Skin Cancer), Breast Cancer, Brain Metastasases
What this study did
NCT05508906 · Olema Pharmaceuticals, Inc.
2022-08-31 – 2028-01-31 · Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT04188548 · Eli Lilly and Company
2019-12-10 – 2027-12 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
What this study did
NCT05143229 · University of Kansas Medical Center
2022-03-28 – 2026-12 · Breast Cancer
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03207529 · M.D. Anderson Cancer Center
2019-06-07 – 2023-12-31 · Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Androgen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, PTEN Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma
What this study did
NCT01791478 · Vanderbilt-Ingram Cancer Center
2013-04 – 2022-10-06 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01870505 · Memorial Sloan Kettering Cancer Center
2013-05 – 2022-02-28 · Metastatic or Locally-advanced Unresectable Breast Cancer
What this study did
NCT02734615 · Novartis Pharmaceuticals
2016-06-14 – 2021-09-13 · Advanced or Metastatic ER+ Breast Cancer
What this study did
NCT01219699 · Novartis Pharmaceuticals
2010-10-05 – 2020-04-16 · Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
What this study did
NCT02077933 · Novartis Pharmaceuticals
2014-05-14 – 2019-04-12 · Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
What this study did
NCT01300962 · UNC Lineberger Comprehensive Cancer Center
2011-08 – 2018-12-31 · Metastatic Breast Cancer
What this study did
NCT02058381 · Novartis Pharmaceuticals
2014-05-06 – 2018-06-19 · Pre-menopausal Breast Cancer, PI3K Pathway Inhibition
What this study did
NCT02088684 · Novartis Pharmaceuticals
2014-05-19 – 2018-04-17 · Breast Cancer
What this study did
NCT02038010 · Northwestern University
2014-05-21 – 2017-05-20 · HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02051751 · Novartis Pharmaceuticals
2014-03-05 – 2016-08-19 · Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
What this study did
Other / comorbidity
NCT03631953 · Assistance Publique Hopitaux De Marseille
2019-09-30 – 2028-12-30 · Meningioma
What this study did
NCT07778524 · Columbia University
2026-09-02 – 2028-08-31 · Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
What this study did
NCT05472220 · Pamela Munster
2022-11-01 – 2028-04-30 · Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation, Human Papillomavirus-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
What this study did
NCT06354088 · Columbia University
2024-04-24 – 2026-12-31 · Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
What this study did
NCT05733455 · Columbia University
2023-05-09 – 2023-12-01 · Insulin Resistance, Hyperinsulinemia, Dyslipidemias
What this study did
NCT05195892 · Novartis Pharmaceuticals
2022-02-03 – 2022-11-09 · Healthy Volunteers
What this study did
NCT02282371 · Memorial Sloan Kettering Cancer Center
2014-10-30 – 2021-10-22 · Head and Neck Squamous Cell Cancer
What this study did
NCT02537223 · University Health Network, Toronto
2015-09 – 2020-02-20 · Squamous Cell Carcinoma of Head and Neck, Locoregionally Advanced
What this study did
NCT02155088 · H. Lee Moffitt Cancer Center and Research Institute
2014-10-30 – 2020-01-31 · Pancreatic Cancer
What this study did
NCT02620839 · Pamela Munster
2016-12-01 – 2019-01-28 · Solid Tumors
What this study did
NCT02550743 · howard safran
2016-06-03 – 2018-11-16 · Rectal Cancer
What this study did
NCT01735968 · Novartis Pharmaceuticals
2013-02-27 – 2018-10-19 · 3rd Line GIST
What this study did
NCT02273219 · Columbia University
2014-11-19 – 2018-07-02 · Uveal Melanoma
What this study did
NCT02624557 · Novartis Pharmaceuticals
2015-12-21 – 2017-10-01 · Hepatic Impairment
What this study did
NCT01449058 · Array BioPharma
2012-03 – 2017-08-15 · Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
What this study did
NCT01928459 · Novartis Pharmaceuticals
2013-10 – 2016-08 · Advanced Solid Tumors, Metastatic Solid Tumors
What this study did
NCT01822613 · Novartis Pharmaceuticals
2013-07-26 – 2016-06-03 · Esophageal Squamous Cell Carcinoma
What this study did
NCT01387321 · Novartis Pharmaceuticals
2011-09-22 – 2015-11-25 · Advanced Solid Tumor
What this study did
NCT02144038 · Novartis Pharmaceuticals
2014-07-23 – 2015-10-28 · Relapsed and Refractory Multiple Myeloma
What this study did
NCT01613950 · Novartis Pharmaceuticals
2012-12 – 2014-03 · Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
What this study did
Phase 4 (1)
Early phase / not applicable (3)
HR+/HER2- Metastatic Breast Cancer
NCT05107388 · Centre Hospitalier Universitaire de Besancon
2021-12 – 2024-03 · Breast Cancer, Diabetes
What this study did
Other / comorbidity
NCT03138070 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2017-10-20 – 2025-11-26 · Head and Neck Squamous Cell Cancer
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT03386162 · UNICANCER
2018-03-15 – 2022-11-18 · Breast Cancer, PI3K, Alpelisib
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Alpelisib (BYL719): this drugApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 40 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Alpelisib (BYL719) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
Phase 1Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06354088 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
2027 (12)
January 2027 (3)
Phase 2Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations, Venous Malformation, Lymphatic Malformation …Recruiting
Est. primary completion 2027-01 · NCT05983159 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01-28 · NCT05038735 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01-29 · NCT04544189 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT01872260 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT04524000 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT04208178 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)Recruiting
Est. primary completion 2027-03 · NCT05577754 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2PIK3CA-related Overgrowth Spectrum (PROS)Active not recruiting
Est. primary completion 2027-06-22 · NCT04980833 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08-03 · NCT06545682 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-08 · NCT05090358 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT05508906 · CT.gov ↗
What to watch
2028 (4)
May 2028 (2)
Phase 2Endometroid Endometrial CancerActive not recruiting
Est. primary completion 2028-05-01 · NCT05154487 · CT.gov ↗
What to watch
Phase 2/3Lymphatic MalformationsRecruiting
Est. primary completion 2028-05-31 · NCT05948943 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult ParticipantsRecruiting
Est. primary completion 2028-08-31 · NCT07778524 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 2PIK3CA-related Overgrowth Spectrum (PROS)Recruiting
Est. primary completion 2029-01-29 · NCT06997588 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Vascular Anomalies, Vascular Anomaly, TIE2/PIK3CA Pathway Driven Vascular AnomaliesRecruiting
Est. primary completion 2029-10-27 · NCT07543822 · CT.gov ↗
What to watch
2030 (2)
July 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-10 · NCT05933395 · CT.gov ↗
What to watch
2032 (1)
March 2032 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2032-03-23 · NCT07679269 · CT.gov ↗
What to watch

See the full readout calendar ↗